ATC CODE L04AX02

THALIDOMIDE

Θαλιδομίδη

Φαρμακολογικό Προφίλ

Πηγή: DrugBank

Περιγραφή & Ένδειξη

A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action. [PubChem]

Κύρια Ένδειξη

For the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.

Χρόνος Ημιζωής

Themeanhalf-lifeofeliminationrangesfromapproximately5to7hfollowingasingledoseandisnotaltereduponmultipledosing.

The mean half-life of elimination ranges from approximately 5 to 7 hours following a single dose and is not altered upon multiple dosing.

Σύνδεση Πρωτεϊνών

55% and 66% for the (+)R and (−)S enantiomers, respectively.

Δείτε αναλυτικό φαρμακολογικό προφίλ.

+ Περισσότερες Φαρμακολογικές Πληροφορίες

Μηχανισμός Δράσης

In patients with erythema nodosum leprosum (ENL) the mechanism of action is not fully understood. Available data from in vitro studies and preliminary …